Amsterdam Neuroscience
-
Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE)
Hof, S., van Rijn, L. J., Uitdehaag, B. M. J., Nij Bijvank, J. A. & Petzold, A., 30 Jan 2024, In: BMJ Open. 14, 1, p. e076651 e076651.Research output: Contribution to journal › Article › Academic › peer-review
-
Reply: Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation
Keddie, S., Smyth, D., Keh, R. Y. S., Wieske, L., Michael, M., Eftimov, F., Bellanti, R., Rinaldi, S., Petzold, A. & Lunn, M. P., 1 Jan 2024, In: Brain. 147, 1, p. E3-E4Research output: Contribution to journal › Letter › Academic › peer-review
-
Exploring Vitreous Haze as a Potential Biomarker for Accelerated Glymphatic Outflow and Neurodegeneration in Multiple Sclerosis: A Cross-Sectional Study
Kaçar, S., Coric, D., Ometto, G., Montesano, G., Denniston, A. K., Keane, P. A., Uitdehaag, B. M. J., Crabb, D. P., Schoonheim, M. M., Petzold, A. & Strijbis, E. M. M., 30 Dec 2023, In: Brain sciences. 14, 1Research output: Contribution to journal › Article › Academic › peer-review
- All publications